Toggle Offcanvas
...
 
Ranibizumab Tenders

Ranibizumab Tenders

View Ranibizumab tenders, RFPs and contracts. Bid on readily available Ranibizumab tenders with the best and most comprehensive tendering platform, since 2002.

Bidding for Ranibizumab tenders is extremely lucrative for companies of all sizes. Tendering authorities and private companies release thousands of contracts worth millions for procurement of Ranibizumab.

Global Tenders stands out as the largest platform dedicated to pharmaceutical tenders and government contracts. Boasting over 20 years of experience in the tender business, GlobalTenders offers the most extensive and reliable Tenders/RFPs/Contracts Database available. The platform aggregates contracts from both public and private sources, connecting with a vast network of over half a million buyers. Employing advanced artificial intelligence, our meticulous process involves gathering information from over a hundred thousand sources. The data is then intelligently categorized into thousands of subcategories for easy filtering and presenting it in a user-friendly format for quick comprehension.

In addition to tender information, we offer in-depth Ranibizumab market analysis, bid consultancy services, and insights into top bidders and winners.

Sign up now to get instant access to unlimited Ranibizumab tenders, advanced search filters, market analysis, industry trends, tender training and 24/7 customer support.

33 Live Notices for Ranibizumab Tenders

Showing 1 to 20

Open-House Biologika Discount Contracts 2025-24-Ranibizumab
country Germany
posting date28 Sep 2025
deadline31 Oct 2026
Subject: Electronic Auction - The Object Of The Bidding Is The Price Registration For Future And Eventual Acquisitions Of Medicines, Under The Conditions Established In This Notice And Its Attachments.
country Brazil
posting date23 Sep 2025
deadline08 Oct 2025
Object: Electronic Auction - Acquisition Of Beclomethasone (Dipropionate) 50 Mcg/Dose Fr 200 Doses (*), Triancinolone 55 Mcg Aqueous Spray Vial 120 Dose (*), 1 Mg/Ml Oral Solution Fr 100 Ml (*), Cetirizine (Dichloride) (*), Ranibizumab 2.3 Mg/0.23 Ml Sol Inj Intravitrea Fa (*), Aflibercepte 2 Mg/0.05 Ml Sol Inj Intravitrea Fa (*).
country Brazil
posting date20 Sep 2025
deadline04 Oct 2025
Delivery Of Medicinal Products To The Drug Program - Treatment Of Patients With Retinal Diseases
country Poland
posting date19 Sep 2025
deadline03 Oct 2025
Open House Pharmaceutical Discount Contracts To The Active Ingredient Ranibizumab, As A Piercing Bottle, Atc S01La04
country Germany
posting date11 Apr 2025
deadline31 Mar 2027
Open House Pharmaceutical Discount Contracts To The Active Ingredient Ranibizumab, As A Piercing Bottle, Atc S01La04
country Germany
posting date11 Apr 2025
deadline31 Mar 2027
Open House Pharmaceutical Discount Contracts To The Active Ingredient Ranibizumab, As A Piercing Bottle, Atc S01La04
country Germany
posting date11 Apr 2025
deadline31 Mar 2027
Open House Pharmaceutical Discount Contracts To The Active Ingredient Ranibizumab, As A Piercing Bottle, Atc S01La04
country Germany
posting date11 Apr 2025
deadline31 Mar 2027
Open House Pharmaceutical Discount Contracts To The Active Ingredient Ranibizumab, As A Piercing Bottle, Atc S01La04
country Germany
posting date11 Apr 2025
deadline31 Mar 2027
Open House Pharmaceutical Discount Contracts To The Active Ingredient Ranibizumab, As A Piercing Bottle, Atc S01La04
country Germany
posting date11 Apr 2025
deadline31 Mar 2027
Open House Pharmaceutical Discount Contracts To The Active Ingredient Ranibizumab, As A Piercing Bottle, Atc S01La04
country Germany
posting date11 Apr 2025
deadline31 Mar 2027
Open House Pharmaceutical Discount Contracts To The Active Ingredient Ranibizumab, As A Piercing Bottle, Atc S01La04
country Germany
posting date11 Apr 2025
deadline31 Mar 2027
Open House Pharmaceutical Discount Contracts To The Active Ingredient Ranibizumab, As A Piercing Bottle, Atc S01La04
country Germany
posting date11 Apr 2025
deadline31 Mar 2027
Open House Pharmaceutical Discount Contracts To The Active Ingredient Ranibizumab, As A Piercing Bottle, Atc S01La04
country Germany
posting date11 Apr 2025
deadline31 Mar 2027
Open House Pharmaceutical Discount Contracts To The Active Ingredient Ranibizumab, As A Piercing Bottle, Atc S01La04
country Germany
posting date11 Apr 2025
deadline31 Mar 2027
Open House Pharmaceutical Discount Contracts To The Active Ingredient Ranibizumab, As A Piercing Bottle, Atc S01La04
country Germany
posting date11 Apr 2025
deadline31 Mar 2027
Open House Pharmaceutical Discount Contracts To The Active Ingredient Ranibizumab, As A Piercing Bottle, Atc S01La04
country Germany
posting date11 Apr 2025
deadline31 Mar 2027
Open House Pharmaceutical Discount Contracts To The Active Ingredient Ranibizumab, As A Piercing Bottle, Atc S01La04
country Germany
posting date11 Apr 2025
deadline31 Mar 2027
Open House Pharmaceutical Discount Contracts To The Active Ingredient Ranibizumab, As A Piercing Bottle, Atc S01La04
country Germany
posting date11 Apr 2025
deadline31 Mar 2027
Open House Pharmaceutical Discount Contracts To The Active Ingredient Ranibizumab, As A Piercing Bottle, Atc S01La04
country Germany
posting date11 Apr 2025
deadline31 Mar 2027

Share Share this page